Chad Phipps Sells 3,000 Shares of Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded up $0.56 during mid-day trading on Wednesday, reaching $94.78. The company had a trading volume of 1,994,494 shares, compared to its average volume of 2,265,184. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The firm has a market cap of $18.08 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 1.85 and a beta of 0.47. The company has a 50 day moving average of $95.12 and a 200-day moving average of $91.59. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $106.88.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp bought a new stake in shares of Zimmer Biomet in the second quarter worth about $922,000. Hsbc Holdings PLC acquired a new stake in shares of Zimmer Biomet during the second quarter worth about $35,417,000. PNC Financial Services Group Inc. lifted its holdings in shares of Zimmer Biomet by 9.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC lifted its holdings in shares of Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock valued at $5,204,000 after purchasing an additional 40,610 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Zimmer Biomet by 257.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after purchasing an additional 24,748 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ZBH shares. Canaccord Genuity Group lifted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Truist Financial upped their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Citigroup reduced their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.